N,N'-di-(m-methylphenyi)-3,6-dimethyl-1,4-dihydro-1,2,4,5-tetrazine-1,4-dicarboamide (ZGDHu-1) suppresses the proliferation of PANC-1 pancreatic cancer cells via apoptosis and G2/M cell cycle arrest

Chen,Su-Feng; Xia,Jun; Lv,Ya-Ping; Liu,Jin-Lin; Li,Wan-Xiang; Yu,Xi-Ping; Hu,Wei-Xiao; Zhou,Yong-Lie

doi:10.3892/or.2015.3803

N,N'-di-(m-methylphenyi)-3,6-dimethyl-1,4-dihydro-1,2,4,5-tetrazine-1,4-dicarboamide (ZGDHu-1) suppresses the proliferation of PANC-1 pancreatic cancer cells via apoptosis and G2/M cell cycle arrest

Authors:
- Su-Feng Chen
- Jun Xia
- Ya-Ping Lv
- Jin-Lin Liu
- Wan-Xiang Li
- Xi-Ping Yu
- Wei-Xiao Hu
- Yong-Lie Zhou
View Affiliations

Affiliations: Zhejiang Chinese Medical University, Hangzhou, Zhejiang, P.R. China, Clinical Laboratory Center, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, P.R. China, College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, Zhejiang, P.R. China
Published online on: February 16, 2015 https://doi.org/10.3892/or.2015.3803
Pages: 1915-1921

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer is one of the human gastrointestinal malignancies with a high mortality and poor prognosis. Approximately eighty percent of patients are diagnosed with unresectable or metastatic disease. Thus, development of novel chemicals in the treatment of pancreatic cancer is imperative. This study aimed to investigate the anticancer effects of N,N'-di-(m-methylphenyi)-3,6-dimethyl-1,4-dihydro-1,2,4,5-tetrazine-1,4-dicarboamide (ZGDHu-1), a new tetrazine derivative, on the PANC-1 pancreatic cancer cell line and clarify the underlying molecular mechanism. Using an MTT assay, we found that ZGDHu-1 significantly suppressed the proliferation of PANC-1 cells in a time- and dose-dependent manner. Moreover, according to the morphological and flow cytometric analysis, the results indicated that ZGDHu-1 induced PANC-1 cell apoptosis and G2/M cell cycle arrest in a dose-dependent manner. In the western blot analysis, expression of the pro-apoptotic Bax gene was upregulated while the anti-apoptotic Bcl-2 gene was downregulated following treatment with ZGDHu-1. ZGDHu-1 also activated pro-caspase-3 and PARP and increased the expression of NF-κB inhibitor IκB. Furthermore, the expression levels of G2/M regulatory molecules such as cyclin B1 and cdc2 were decreased while that of Chk1 was increased. These results suggested that ZGDHu-1 suppressed the proliferation of pancreatic cancer cells, rendering it a potential therapeutic drug for the treatment of pancreatic cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 62:283–298. 2012. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
3	Chen WQ, Liang D, Zhang SW, Zheng RS and He YT: Pancreatic cancer incidence and mortality patterns in China, 2009. Asian Pac J Cancer Prev. 14:7321–7324. 2013. View Article : Google Scholar
4	Ma C, Jiang YX, Liu SZ, et al: Trend and prediction on the incidence of pancreatic cancer in China. Zhonghua Liu Xing Bing Xue Za Zhi. 34:160–163. 2013.(In Chinese). PubMed/NCBI
5	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
7	Neoptolemos JP, Dunn JA, Stocken DD, et al: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 358:1576–1585. 2001. View Article : Google Scholar : PubMed/NCBI
8	Van Laethem JL, Hammel P, Mornex F, et al: Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 28:4450–4456. 2010. View Article : Google Scholar : PubMed/NCBI
9	Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
10	Rao GW and Hu WX: Synthesis, X-ray crystallographic analysis, and antitumor activity of 1-acyl-3,6-disubstituted phenyl-1,4-dihydro-1,2,4,5-tetrazines. Bioorg Med Chem Lett. 15:3174–3176. 2005. View Article : Google Scholar : PubMed/NCBI
11	Rao GW and Hu WX: Synthesis, structure analysis, and antitumor activity of 3,6-disubstituted-1,4-dihydro-1,2,4,5-tetrazine derivatives. Bioorg Med Chem Lett. 16:3702–3705. 2006. View Article : Google Scholar : PubMed/NCBI
12	Zhou YL, Lü YP, Hu WX, et al: ZGDHu-1-inducing apoptosis of SHI-1 leukemia cells and its molecular mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 15:483–489. 2007.(In Chinese). PubMed/NCBI
13	Zhou YL, Hu WX, Lü YP, et al: Effect of ZGDHu-1 on proliferation and apoptosis of A549 cells in vitro and antitumor activity in vivo. Yao Xue Xue Bao. 42:26–34. 2007.(In Chinese). PubMed/NCBI
14	Tchoghandjian A, Jennewein C, Eckhardt I, Momma S, Figarella-Branger D and Fulda S: Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-κB. Cell Death Differ. 21:735–747. 2014. View Article : Google Scholar : PubMed/NCBI
15	Loos M, Kleeff J, Friess H and Büchler MW: Surgical treatment of pancreatic cancer. Ann NY Acad Sci. 1138:169–180. 2008. View Article : Google Scholar : PubMed/NCBI
16	Neoptolemos JP, Stocken DD, Bassi C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 304:1073–1081. 2010. View Article : Google Scholar : PubMed/NCBI
17	Zhang YX, Zhou YL, Xu F and Qiu LN: Effect of ZGDHu-1 on proliferation of K562 and K562/Adr and the expression of NF-κB protein. Bull Med Res. 40:50–54. 2011.(In Chinese).
18	Abraham E: NF-kappaB activation. Crit Care Med. 28(Suppl 4): N100–N104. 2000. View Article : Google Scholar : PubMed/NCBI
19	Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
20	Nyberg KA, Michelson RJ, Putnam CW and Weinert TA: Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet. 36:617–656. 2002. View Article : Google Scholar : PubMed/NCBI
21	Bartek J and Lukas J: Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 3:421–429. 2003. View Article : Google Scholar : PubMed/NCBI
22	Arlt A, Muerkoster SS and Schafer H: Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 332:346–358. 2013. View Article : Google Scholar
23	Bai L and Wang S: Targeting apoptosis pathways for new cancer therapeutics. Annu Rev Med. 65:139–155. 2014. View Article : Google Scholar
24	Shamas-Din A, Kale J, Leber B and Andrews DW: Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb Perspect Biol. 5:a0087142013. View Article : Google Scholar : PubMed/NCBI
25	Wen X, Lin ZQ, Liu B and Wei YQ: Caspase-mediated programmed cell death pathways as potential therapeutic targets in cancer. Cell Prolif. 45:217–224. 2012. View Article : Google Scholar : PubMed/NCBI
26	Langelier MF, Planck JL, Roy S and Pascal JM: Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science. 336:728–732. 2012. View Article : Google Scholar : PubMed/NCBI